Key result
N-acetylprocainamide reduces upstroke velocity at low concentrations, demonstrating class IA rather than class III actions.
Why the study?
N-acetylprocainamide is widely described as a pure class III antiarrhythmic, but conflicting evidence in other species suggests it affects cardiac Na+ channels.
Does N-acetylprocainamide act as a pure class III antiarrhythmic in guinea pig papillary muscle?
Does N-acetylprocainamide act as a pure class III antiarrhythmic in guinea pig papillary muscle?
The finding challenges the classic textbook concept that NAPA is a pure class III antiarrhythmic, demonstrating species-dependent class IA behavior explained by molecular steric hindrance.
Answers are grounded in this paper and cite their sources.
NAPA exhibits class IA effects in guinea pig tissue; leaves open translation to human arrhythmias or antiarrhythmic selection.
Procainamide (PA) and its in vivo metabolite, N-acetylprocainamide (NAPA), display some pharmacological differences. Although it is agreed that PA is a class IA antiarrhythmic, it has been reported that NAPA is a pure class III antiarrhythmic that affects only the repolarizing phase of the cardiac action potential. This last concept, observed exclusively in dogs, gained wide acceptance, appearing in classic pharmacology textbooks. However, evidence in species such as mice and rats indicates that NAPA can affect cardiac Na+ channels, which is unexpected for a pure class III antiarrhythmic drug. To further clarify this issue, the effects of PA (used as a reference drug) and NAPA on the maximum upstroke velocity (Vmax) and half-decay time (HDT) of the cardiac action potential were examined in the isolated right papillaris magnus of the guinea pig heart. Both PA and NAPA affected Vmax at lower concentrations than required to affect HDT, and NAPA had weaker effects on both variables. Thus, NAPA displayed typical class IA antiarrhythmic behavior. Therefore, the concept that NAPA is a pure class III antiarrhythmic drug is more species-dependent than previously envisioned. In addition, we demonstrated that the differential pharmacology of PA and NAPA is explainable, in molecular terms, by steric hindrance of the effects of NAPA and the greater number of potent aromatic-aromatic and cation π interactions with Na+ or K+ cardiac channels for PA.
No takes yet. Share an insight, caveat, or question.
Sigler et al. (2023) studied this question. N-acetylprocainamide (NAPA) vs. Procainamide (PA) and drug-free solution was evaluated on Maximum upstroke velocity (Vmax) and half-decay time (HDT) of the cardiac action potential. N-acetylprocainamide decreased maximum upstroke velocity at lower concentrations than required to affect half-decay time, demonstrating class IA rather than pure class III antiarrhythmic properties.
Synapse has enriched 10 related papers. Consider them for comparative context: